{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:52:56Z","timestamp":1772902376749,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012554","name":"Hubei Provincial Department of Education","doi-asserted-by":"publisher","award":["B2017024"],"award-info":[{"award-number":["B2017024"]}],"id":[{"id":"10.13039\/100012554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017718","name":"Natural Science Foundation of Yichang City","doi-asserted-by":"publisher","award":["A20-2-002"],"award-info":[{"award-number":["A20-2-002"]}],"id":[{"id":"10.13039\/100017718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.nefroe.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:38:58Z","timestamp":1683286738000},"page":"731-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Xuanwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanjiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.04.002_bib0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0185","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Human Genet"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0190","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1681\/ASN.2016121312","article-title":"Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2","volume":"28","author":"Cabezas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0195","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0205","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000487899","article-title":"Novel mutations in the PKD1 and PKD2 genes of Chinese patients with autosomal dominant polycystic kidney disease","volume":"43","author":"Xu","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0220","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0225","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0230","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 44 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0245","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ndt\/gfy298","article-title":"Con: tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?","volume":"34","author":"Gross","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13730-016-0245-y","article-title":"Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease","volume":"6","author":"Morimoto","year":"2017","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0260","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0265","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0270","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","article-title":"Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial","volume":"69","author":"Casteleijn","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10157-020-02009-0","article-title":"Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease","volume":"25","author":"Horie","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0280","article-title":"Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: a pilot study","author":"Lai","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0285","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","article-title":"The NOCTURNE randomized trial comparing 2 tolvaptan formulations","volume":"5","author":"Perrone","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0290","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","article-title":"The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3: 4 trial","volume":"19","author":"Muto","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0300","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1681\/ASN.2004121079","article-title":"Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans","volume":"16","author":"Bankir","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0305","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0310","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00424-017-2002-2","article-title":"Regulation of renal Na-(K)-Cl cotransporters by vasopressin","volume":"469","author":"Bachmann","year":"2017","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0320","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2011-04-347328","article-title":"Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease","volume":"118","author":"Blumenfeld","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0325","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0330","doi-asserted-by":"crossref","first-page":"e92232","DOI":"10.1371\/journal.pone.0092232","article-title":"Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease","volume":"9","author":"Chen","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/STROKEAHA.110.578740","article-title":"Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease","volume":"42","author":"Xu","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0340","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0345","doi-asserted-by":"crossref","first-page":"F1463","DOI":"10.1152\/ajprenal.90266.2008","article-title":"Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor","volume":"295","author":"Wallace","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2023.04.002_bib0350","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:32:37Z","timestamp":1746189157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2013251423000718"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.04.002","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}